strain
vaccinia
viru
activ
ingredi
japanes
smallpox
vaccin
deriv
listerelstre
strain
replicationcompet
administ
infant
adult
seriou
advers
reaction
despit
outstand
safeti
profil
occurr
spontaneouslygener
larg
plaqueform
virul
revert
follow
passag
cell
cultur
major
drawback
identifi
gene
respons
revers
delet
gene
deriv
nonpathogen
immunodefici
sever
combin
immunodefici
scid
mice
geneticallyst
revers
largeplaqu
phenotyp
upon
passag
cell
cultur
even
condit
popul
replac
revert
moreov
effect
nonrepl
vaccinia
viru
vv
modifi
vaccinia
ankara
mva
induc
murin
immun
respons
pathogen
vv
express
siv
gag
gene
also
induc
antigag
tcell
effici
mva
anoth
nonrepl
vv
dairen
minutepock
variant
di
moreov
express
env
combin
sendai
viru
vector
induc
product
antienv
antibodi
tcell
thu
safeti
efficaci
mean
repres
outstand
platform
develop
human
vaccin
vector
smallpox
erad
worldwid
howev
seriou
public
health
concern
due
threat
bioterror
natur
outbreak
monkeypox
start
centuri
highlight
necess
vaccinia
viru
vv
base
smallpox
vaccin
exist
vaccin
stockpil
updat
sinc
earli
vaccin
lymphderiv
vaccin
produc
propag
vaccin
virus
skin
anim
ie
firstgener
vaccin
tabl
meet
good
manufactur
practic
gmp
standard
therefor
risk
adventiti
microbi
contamin
moreov
vaccin
occasion
caus
seriou
advers
effect
eg
progress
vaccinia
eczema
vaccinatum
postvaccini
enceph
due
pathogen
vaccin
virus
use
address
issu
outlin
much
effort
gone
develop
safer
smallpox
vaccin
candid
studi
aim
gener
vaccin
use
steril
cell
cultur
techniqu
reduc
risk
contamin
adventiti
agent
secondgener
vaccin
see
tabl
exampl
propag
cell
diploid
human
lung
fibroblast
use
singl
clone
vv
isol
dryvax
calf
lymph
vaccin
manufactur
wyeth
laboratori
use
new
york
citi
board
health
nycbh
prepar
vero
cell
serumfre
condit
use
seed
viru
cellcultur
smallpox
vaccin
ccsv
deriv
plaquepurifi
nycbh
strain
also
prepar
cell
elstreebn
vaccin
manufactur
chicken
embryo
fibroblast
cef
use
listerelstre
lister
strain
wide
use
lymphderiv
vaccin
europ
africa
asia
global
smallpox
erad
campaign
manufactur
vaccin
cell
cultur
reduc
risk
vaccin
contamin
extran
agent
howev
secondgener
vaccin
manufactur
use
firstgener
vaccin
isol
seed
virus
safeti
profil
equival
origin
lymphderiv
vaccin
ie
caus
advers
event
global
smallpox
erad
campaign
progress
risk
contract
smallpox
infect
diminish
develop
countri
began
rais
concern
side
effect
associ
lymphderiv
smallpox
vaccin
trigger
new
research
develop
altern
attenu
vaccin
thirdgener
vaccin
modifi
vaccinia
ankara
mva
dairen
minutepock
variant
di
lister
clone
main
method
use
attenu
vv
serial
passag
primari
cell
cultur
egg
mva
attenu
serial
passag
chorioallantoi
vv
ankara
strain
cef
time
result
loss
approxim
genom
includ
host
rangerel
gene
immunomodulatori
gene
therebi
gener
phenotyp
unabl
replic
mammalian
cell
mva
show
extrem
attenu
phenotyp
anim
human
administ
individu
western
germani
turkey
global
erad
campaign
appar
side
effect
although
abil
protect
smallpox
infect
proven
time
need
smallpox
vaccin
safe
use
immunocompromis
individu
includ
aid
patient
patient
treat
chemotherapi
transplant
recipi
meant
mva
examin
number
clinic
trial
data
clinic
trial
anim
experi
suggest
although
mvaderiv
vaccin
extrem
good
safeti
profil
less
immunogen
replicationcompet
vv
dryvax
exampl
data
anim
model
show
multipl
log
higher
dose
mva
requir
elicit
antibodi
titer
compar
elicit
replicationcompet
vv
di
strain
origin
dairen
strain
smallpox
vaccin
strain
japan
isol
smallsiz
pock
form
variant
chick
chorioallanto
membran
cam
passag
onedayold
egg
case
mva
di
harbor
larg
delet
within
left
termin
region
genom
contain
host
rang
gene
immunomodulatori
gene
consequ
di
lack
abil
replic
number
mammalian
cell
type
although
di
show
good
safeti
profil
test
field
trial
involv
japanes
children
adopt
smallpox
vaccin
less
immunogen
lister
clone
concern
regard
side
effect
firstgener
smallpox
vaccin
ikeda
dairen
lister
becom
problem
japan
respons
demand
safer
still
effect
vaccin
chiba
serum
institut
develop
highli
attenu
strain
call
form
minut
pock
cam
embryon
egg
isol
lister
lister
origin
lo
strain
via
intermedi
strain
deriv
test
rabbit
monkey
model
show
markedli
less
neurovirul
firstgener
vaccin
strain
lo
dryvax
inde
virul
compar
replicationdefect
di
moreov
induc
much
weaker
dermal
reaction
rabbit
human
show
lower
rate
febril
reaction
direct
parent
clinic
trial
administr
approxim
infant
without
seriou
advers
reaction
prove
immunogen
parent
lo
strain
therefor
adopt
favor
vaccin
strain
japan
number
novel
attenu
approach
involv
direct
modif
vv
genom
use
genet
engin
techniqu
use
develop
highli
attenu
vv
strain
fourthgener
vaccin
nyvac
method
replac
classic
attenu
method
base
serial
passag
primari
cell
cultur
egg
nyvac
deriv
copenhagen
vv
vaccin
strain
delet
nonessenti
gene
includ
host
rang
gene
thymidin
kinas
gene
gene
relat
viral
dna
synthesi
gene
encod
larg
subunit
ribonucleotid
reductas
thu
nyvac
show
restrict
replic
mammalian
cell
highli
attenu
phenotyp
anim
howev
sinc
replic
nyvac
nonpermiss
mammal
cell
arrest
earli
stage
case
avipoxvirus
canari
poxviru
fowl
poxviru
elicit
weaker
immun
respons
mva
replicationcompet
vv
categor
fourthgener
vaccin
obtain
parent
smallpox
vaccin
strain
delet
gene
respons
revers
consequ
show
good
genet
stabil
littl
revers
howev
retain
abil
replic
mammalian
cell
takahashinishimaki
et
al
first
identifi
vv
gene
respons
largeplaqu
format
replic
vero
cell
cours
investig
mechan
attenu
gener
harbor
frameshift
mutat
due
singl
base
delet
middl
open
read
frame
orf
mutat
result
loss
function
encod
glycoprotein
protein
involv
packag
intracellular
matur
virion
imv
within
transgolgi
membran
endosom
cisterna
form
intracellular
envelop
virion
iev
iev
transport
along
microtubul
cell
peripheri
adher
cell
membran
cellassoci
envelop
virion
cev
protein
cooper
protein
also
particip
src
kinasedepend
format
actincontain
microvilli
subsequ
releas
cev
cell
surfac
form
extracellular
envelop
virion
eev
despit
rel
pauciti
whole
progeni
virion
eev
play
import
role
dissemin
within
host
sinc
antibodi
neutral
eev
vv
propos
effect
smallpox
vaccin
gener
perform
basic
research
found
vaccin
spontan
revert
largeplaqueform
clone
lpc
thu
concern
lpc
contamin
might
ruin
safeti
profil
futur
vaccin
therefor
investig
molecular
mechan
underli
revers
focu
gene
associ
format
larg
plaqu
isol
three
lpc
clone
vaccin
stock
examin
phenotyp
term
plaqu
size
dermal
reaction
rabbit
pathogen
sever
combin
immunodefici
scid
mice
phenotyp
compar
parent
viru
retain
fullyfunct
gene
three
lpc
virus
show
phenotyp
similar
result
better
growth
cell
cultur
greater
virul
scid
mice
expect
sequenc
lpc
reveal
orf
contain
singl
base
insert
upstream
nucleotid
delet
noteworthi
nucleotid
insert
site
lpc
orf
differ
three
clone
even
though
origin
viral
stock
prepar
seven
passag
clone
result
strongli
suggest
revers
multiclon
event
may
occur
frequent
prevent
gener
revert
decid
delet
entir
gene
genom
homolog
recombin
yield
phenotyp
plaqu
size
dermal
reaction
rabbit
similar
intraperiton
ip
inject
pfu
dose
three
log
higher
need
elicit
protect
immun
balbc
mice
caus
symptom
scid
mice
eightweek
period
figur
mva
plaquepurifi
contain
low
level
revert
also
nonpathogen
howev
deriv
construct
reintroduc
intact
gene
caus
sever
rash
death
scid
mice
even
administ
dose
two
log
lower
figur
genet
stabil
evalu
serial
passag
primari
rabbit
kidney
prk
cell
use
gener
vaccin
detect
lpc
emerg
test
condit
includ
use
vaccin
product
passag
prk
cell
contrast
lpc
emerg
plaquepurifi
immedi
test
figur
note
lpc
appear
cultur
lpc
ratio
increas
rapidli
passag
number
figur
lpc
largeplaqueform
clone
protect
immun
respons
elicit
compar
elicit
dryvax
mva
deriv
express
ectodomain
high
level
mous
model
model
immun
mice
challeng
highli
pathogen
vv
western
reserv
wr
strain
one
popular
method
evalu
efficaci
smallpox
vaccin
figur
immun
group
mice
singl
dose
pfu
vv
via
intramuscular
im
rout
found
level
protect
immun
elicit
compar
elicit
dryvax
superior
elicit
mva
exampl
minim
dose
pfu
dryvax
fulli
protect
mice
lethal
infect
wr
wherea
mice
immun
mva
lost
weight
case
die
maximum
dose
pfu
mva
result
promin
weight
loss
wr
challeng
noteworthi
immun
effici
compar
minim
dose
particular
significantli
inferior
ttest
p
result
suggest
play
major
role
elicit
protect
immun
respons
mice
addit
elicit
protect
immun
respons
cynomolgu
monkey
fulli
protect
lethal
infect
monkeypox
viru
taken
togeth
data
suggest
effect
firstgener
smallpox
vaccin
dryvax
although
sever
studi
report
protein
major
target
eevneutr
antibodi
signific
protect
smallpox
infect
immun
vaccin
virus
protect
anim
lethal
challeng
pathogen
orthopoxvirus
addit
report
show
smallpox
vaccin
alway
induc
antibodi
antibodi
respons
profil
viral
protein
highli
heterolog
human
also
conclud
key
induc
strong
neutral
antibodi
respons
elicit
antibodi
recogn
multipl
viral
protein
antibodi
act
synergist
provid
better
protect
vv
wide
use
vector
express
foreign
gene
mani
excel
properti
high
express
effici
broad
host
rang
larg
capac
accept
foreign
gene
heat
stabil
inexpens
vaccin
product
therefor
vv
vector
examin
use
live
vaccin
human
veterinari
infecti
diseas
cancer
howev
concern
safeti
profil
vv
major
barrier
develop
recombin
vv
vaccin
use
human
research
focus
replicationdefect
poxviru
vector
better
safeti
profil
vehicl
deliv
antigen
deriv
human
pathogen
exampl
avipox
mvaand
nyvacbas
vector
express
compon
human
pathogen
tuberculosi
develop
evalu
monkey
human
howev
although
promis
anim
model
vaccin
induc
suffici
strong
immun
respons
human
protect
human
infect
therefor
effect
vehicl
need
human
vaccin
develop
thu
replicationcompet
vv
proven
safe
human
vaccin
smallpox
could
good
candid
safeti
profil
strong
antigen
geneticallyst
variant
make
promis
vehicl
vaccin
hiv
human
diseas
one
concern
regard
use
viral
vector
preexist
immun
vector
viru
potenti
dampen
specif
immun
respons
howev
kohara
et
al
show
recombin
vaccin
express
sar
coronaviru
sarscov
spike
protein
elicit
neutral
antibodi
sarscov
rabbit
gener
high
titer
antibodi
anoth
report
show
vv
lack
ectodomain
induc
potent
immun
respons
vacciniaimmun
anim
wildtyp
counterpart
result
suggest
would
make
good
vector
viru
elicit
effect
immun
respons
foreign
antigen
individu
preimmun
smallpox
vaccin
previous
develop
promot
atyp
inclus
bodi
ati
complex
promot
compris
ten
repeat
unit
mutat
earli
region
promot
plu
ati
late
promot
complex
promot
possess
strong
activ
earli
late
phase
vv
infect
cycl
inde
h
protein
measl
viru
chloramphenicol
acetyltransferas
synthesi
driven
promot
compris
approxim
total
cellular
protein
moreov
construct
vector
harbor
along
multipl
clone
site
within
hemagglutinin
ha
gene
use
rapid
product
recombin
vitro
ligat
genom
foreign
dna
foreign
gene
insert
stabli
maintain
recombin
construct
techniqu
harbor
promot
sever
passag
cell
standard
cell
line
propag
vv
use
techniqu
test
whether
better
vector
nonrepl
vaccinia
viru
express
siv
gag
gag
protein
siv
major
antigen
elicit
cytotox
lymphocyt
ctl
respons
activ
antigag
ctl
invers
correl
viral
load
individu
experiment
infect
monkey
siv
suggest
strength
antigag
ctl
respons
correl
contain
siv
vector
express
siv
gag
antigen
control
promot
gener
significantli
gag
protein
vitro
elicit
product
antigag
tcell
mice
effici
nonrepl
vv
di
strain
harbor
gag
gene
control
promot
di
strain
immunogen
similar
mva
optim
use
vector
compar
immunogen
siv
gag
protein
express
control
either
promot
promot
classic
earlyl
promot
moder
activ
although
weaker
preliminarili
observ
indic
express
much
foreign
protein
led
reduct
vv
propag
vitro
therefor
balanc
express
foreign
antigen
viral
propag
vivo
might
crucial
optim
immunogen
thu
compar
immunogen
virul
set
recombin
bacillu
calmetteguerin
bcg
primerecombin
boost
vaccin
protocol
set
base
observ
longterm
mainten
effector
memori
tcell
tem
capac
immedi
attack
sivinfect
cell
restrict
infect
antibodyresist
siv
site
viru
entri
achiev
use
vaccin
approach
persist
express
viral
antigen
vaccin
macaqu
via
use
cytomegaloviru
cmv
vector
therebi
result
continu
immun
stimul
sinc
bcg
persist
vaccin
individu
long
period
time
year
without
seriou
symptom
vaccin
bcg
express
gag
protein
may
expect
induc
gagspecif
tcell
maintain
immunolog
memori
via
tem
long
time
vaccin
studi
mice
reveal
less
pathogen
elicit
gagspecif
tcell
effici
tem
detect
even
four
month
boost
therefor
express
siv
gag
control
promot
induc
effici
longlast
immun
respons
harbor
promot
although
induc
antibodi
cytotox
tcell
effect
way
prevent
infect
often
difficult
induc
product
antibodi
particularli
neutral
antibodi
high
titer
exampl
low
titer
env
antibodi
observ
even
repeat
immun
mvabas
vector
repetit
antigen
stimul
requir
affin
matur
process
high
avid
neutral
antibodi
gener
longlast
express
antigen
replicationcompet
vector
may
enabl
repeat
immunolog
present
induc
affin
matur
next
examin
abil
express
env
gene
elicit
antibodi
tcell
mice
set
recombin
prime
follow
sendai
viru
vector
boost
found
vaccin
regimen
led
effici
induct
envspecif
tcell
antienv
antibodi
includ
neutral
antibodi
result
sharp
contrast
report
studi
use
vaccin
regimen
base
prime
envexpress
plasmid
follow
boost
sev
vector
approach
mainli
induc
cellmedi
immun
respons
despit
replicationcompet
phenotyp
highli
attenu
show
pathogen
effect
scid
mice
similar
replicationdefect
vv
mva
howev
compar
effect
smallpox
vaccin
respect
dryvax
moreov
vector
induc
antibodyand
cellmedi
immun
respons
foreign
antigen
effici
nonrepl
vv
vector
therefor
superior
nonrepl
vv
vector
suitabl
use
human
also
point
recombin
may
use
dual
vaccin
smallpox
pathogen
target
insert
gene
